| Literature DB >> 33194517 |
Hiroaki Komuro1,2, Masahiro Yamazoe3, Kosuke Nozaki4, Akiko Nagai5, Tetsuo Sasano1,2.
Abstract
Gene therapy has been explored as a future alternative for treating heart disease. Among several gene delivery systems aimed at penetrating specific target cells, we focused on safe and non-viral gene delivery materials with a high transfection efficiency. Although various techniques have been developed, the mechanisms underlying the cellular uptake of gene delivery materials have not yet been sufficiently studied in cardiomyocytes. The aim of this study was to determine how hydroxyapatite (HAp) nanoparticles contribute to the delivery of plasmid DNA (pDNA) into cardiomyocytes. We fabricated HAp nanoparticles using the water-in-oil (W/O) emulsion method and used these nanoparticles as the delivery vector for transfecting cardiomyocyte-derived HL-1 cells. HAp exhibited particles on the nanoscale and with a low cytotoxicity in HL-1 cells. The transfection assay performed with several endocytosis inhibitors suggested that the HAp/pDNA complexes were internalized by HL-1 cells through macropinocytosis. Furthermore, this HL-1 cell uptake was generated in response to HAp stimulation. Thus, HAp is a positive regulator of macropinocytosis in HL-1 cells and a good system for gene delivery in cardiomyocytes.Entities:
Keywords: cardiomyocyte; endocytosis; gene delivery system; hydroxyapatite nanoparticles; macropinocytosis
Year: 2020 PMID: 33194517 PMCID: PMC7653333 DOI: 10.3762/bjnano.11.150
Source DB: PubMed Journal: Beilstein J Nanotechnol ISSN: 2190-4286 Impact factor: 3.649
Figure 1Characterization of the prepared HAp nanoparticles using the W/O emulsion method. (a) A representative TEM image of HAp nanoparticles. The nanoparticles exhibited uniform size and spherical-like morphology. Scale bar: 100 nm. (b) The size distribution of HAp nanoparticles was determined using nanoparticle tracking analysis (NTA). The mean diameter was 159 ± 47 nm. (c) An X-ray diffractogram of the HAp nanoparticles in the range of 2θ = 20–60°. The spectra revealed the characteristic peaks of HAp according to ICDD no. 09-0432 (vertical lines). (d) The FTIR spectra of the HAp nanoparticles in the range of 4000–400 cm−1. The characteristic peaks of HAp are indicated.
Figure 2MTT assay of HL-1 cells treated with HAp nanoparticles for 24 (white bars) and 72 h (black bars) was used to determine cytotoxicity. Non-treated cells were used as the control. Values are presented as the mean ± SD (n = 4).
Figure 3EGFP gene transfection into HL-1 cells using HAp nanoparticles. (a) Representative fluorescence images of HL-1 cells treated with HAp/pEGFP complexes. The nuclei were stained using Hoechst stain (blue). Scale bar: 100 µm. (b) The transfection efficiency of the complexes 24 h post-transfection. Values are presented as the mean ± SD (n = 4). *p < 0.05.
Figure 4(a) Cytotoxicity assay of HL-1 cells incubated with endocytosis inhibitors for 24 h. (b) Effects of the endocytosis inhibitors on the transfection efficiency of HAp/pEGFP complexes into HL-1 cells. Values are presented as the mean ± SD (n = 4). *p < 0.05.
Figure 5Macropinocytosis activity induced by HAp nanoparticles (1 µg/mL) in HL-1 cells. (a) HL-1 cells were pre-incubated in the presence or absence of HAp for 1, 2, and 4 h, and then treated with TMR–dextran for 30 min. Nuclei were stained using Hoechst stain (blue). Scale bar: 10 µm. (b) Quantification of fluorescence intensity per cell number. Values are presented as the mean ± SD (n = 25). *p < 0.05.